BCL2 and central nervous system cancer: Several strategies, such as small molecule inhibitors, gene therapy, and immunotherapy, have been explored to modulate BAX and Bcl-2 expression and restore caspase-3 activity in glioma cells, with promising results in preclinical studies [28,29,30].